HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Cradle Holdings CEO

This article was originally published in The Rose Sheet

Executive Summary

Fragrance and skin care company appoints Ralph Mason CEO, effective immediately. Mason comes to the firm from Jafra Cosmetics, where he served as chairman and exec VP since 1998. Exec succeeds Robert Nielsen, who has been elected vice chairman of the board, where he will work on "future acquisitions and overall strategy" while remaining a significant investor in the firm. Nielsen served as the first CEO of Cradle Holdings, which was founded in 2002 to "acquire and nurture promising prestige beauty companies" (1"The Rose Sheet" Feb. 18, 2002, p. 7). Cradle Holdings distributes and markets the Erno Laszlo, Penhaligon's and L'Artisan Parfumeur brands...

You may also be interested in...



Penhaligon’s Owner Cradle Holdings Initiates U.S. Expansion

The specialty UK beauty brand Penhaligon's will undergo its first major U.S. expansion under Cradle Holdings, a new cosmetics business entity formed by private equity firm Fox Paine to "acquire and nurture promising prestige beauty companies.

As Casgevy, Lyfgenia Launches Proceed, CRISPR And bluebird bio CEOs Reassure

The CEOs of bluebird bio and CRISPR Therapeutics hope to inspire investor confidence that their gene-based therapies for sickle cell disease and beta thalassemia will be widely reimbursed in the US and EU.

Japan Regulatory Update: Revised Law Widens RWD Scope, Price Revisions/Listings

Japan now allows pseudonymized personal data for medical use under a licensing system for wider use of real-world data. Meanwhile, a national cost-effectiveness assessment scheme has slashed reimbursement prices for Lagevrio and Kerendia, and Alexion’s Voydeya has been added to the reimbursement tariff.

Latest Headlines
See All
UsernamePublicRestriction

Register

RS012294

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel